title: Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy.
authors.forename: Tatiana
authors.initials: T
authors.lastname: Eames
authors.forename: Julia
authors.initials: J
authors.lastname: Kroth
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Flaig
authors.forename: Thomas
authors.initials: T
authors.lastname: Ruzicka
authors.forename: Andreas
authors.initials: A
authors.lastname: Wollenberg
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D000068818:Cetuximab; D002610:Cheek; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005260:Female; D006801:Humans; D009333:Neck; D000077544:Panitumumab; D012867:Skin / Q000187:drug effects / Q000473:pathology; D014973:Xanthomatosis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab